Pure Biologics (Poland) Performance
| PUR Stock | 13.56 0.44 3.14% |
The company holds a Beta of -0.44, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Pure Biologics are expected to decrease at a much lower rate. During the bear market, Pure Biologics is likely to outperform the market. At this point, Pure Biologics Splka has a negative expected return of -0.65%. Please make sure to check Pure Biologics' maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Pure Biologics Splka performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pure Biologics Splka has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Pure |
Pure Biologics Relative Risk vs. Return Landscape
If you would invest 2,155 in Pure Biologics Splka on September 15, 2024 and sell it today you would lose (799.00) from holding Pure Biologics Splka or give up 37.08% of portfolio value over 90 days. Pure Biologics Splka is generating negative expected returns and assumes 4.4517% volatility on return distribution over the 90 days horizon. Simply put, 39% of stocks are less volatile than Pure, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pure Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pure Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pure Biologics Splka, and traders can use it to determine the average amount a Pure Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1456
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PUR |
Estimated Market Risk
| 4.45 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.65 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pure Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pure Biologics by adding Pure Biologics to a well-diversified portfolio.
Things to note about Pure Biologics Splka performance evaluation
Checking the ongoing alerts about Pure Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pure Biologics Splka help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pure Biologics Splka generated a negative expected return over the last 90 days | |
| Pure Biologics Splka has high historical volatility and very poor performance |
- Analyzing Pure Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pure Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Pure Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pure Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pure Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pure Biologics' stock. These opinions can provide insight into Pure Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pure Stock Analysis
When running Pure Biologics' price analysis, check to measure Pure Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pure Biologics is operating at the current time. Most of Pure Biologics' value examination focuses on studying past and present price action to predict the probability of Pure Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pure Biologics' price. Additionally, you may evaluate how the addition of Pure Biologics to your portfolios can decrease your overall portfolio volatility.